Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 8/20 | 0.74 |
| ▸ | AGTR2 | P50052 | 8/20 | 0.74 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.74 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.74 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.74 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787257 | 0.90 | AGTR2 (0.78) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL16239690 | 0.90 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL8468601 | 0.90 | AGTR2 (0.77) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL991961 | 0.89 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL1653541 | 0.89 | AGTR2 (0.72) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL10281258 | 0.89 | AGTR2 (0.76) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL3263977 | 0.88 | AGTR1 (0.57) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL28484414 | 0.86 | AGTR1 (0.59) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL991977 | 0.86 | AGTR1 (0.69) | AGTR1AGTR2ABCC3ABCC4ABCB11 | |
| SCHEMBL1640019 | 0.86 | AGTR2 (0.79) | AGTR1AGTR2ABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2426127-B1 | NOVEL SOLVATE CRYSTALS | DAIICHI SANKYO CO LTD (JP) | 2019-09-04 | — | — | EP | disclosed |
| EP-2891650-B1 | METHOD FOR PRODUCING BIARYL COMPOUND | API CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-9624181-B2 | Method for producing biaryl compound | API CORPORATION (JP) | 2017-04-18 | — | — | US | disclosed |
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-04-14 | — | — | US | disclosed |
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | API CORPORATION (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-2891650-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | API Corporation (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-8933241-B2 | Method for producing olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-13 | — | — | US | disclosed |
| EP-2426126-B1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | DAIICHI SANKYO CO LTD (JP) | 2014-11-19 | — | — | EP | disclosed |
| US-8859600-B2 | Acetone solvate crystals of trityl olmesartan medoxomil | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-10-14 | — | — | US | disclosed |
| US-20120071665-A1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120059172-A1 | NOVEL SOLVATE CRYSTALS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-2426127-A1 | NOVEL SOLVATE CRYSTALS | Daiichi Sankyo Company, Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-2426126-A1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | Daiichi Sankyo Company, Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239853-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | MLX, BMX, BRIX1 | AGTR1 1993/4885AGTR2 954/4885ABCC3 1950/4885 |
| US-20120071665-A1 | METHOD FOR PRODUCING OLMESARTAN MEDOXOMIL | MSMO1, MTPN, REN | AGTR1 14/4885AGTR2 6/4885ABCC3 4413/4885 |
| US-20160102079-A1 | ACETONE SOLVATE CRYSTALS OF TRITYL OMESARTAN MEDOXOMIL | THOP1, MSMO1, HAAO | AGTR1 23/4885AGTR2 29/4885ABCC3 3412/4885 |
| US-20120059172-A1 | NOVEL SOLVATE CRYSTALS | REN, LOXL1, LOXL2 | AGTR1 8/4885AGTR2 14/4885ABCC3 3895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.